Abstract
Evidence-based medicine is defined as an attempt to use standards from
scientifically-collected evidence to improve medical practices by assessing
risks and benefits of treatments and/or the lack of treatments. The term can
be taken to cover a wide variety of recommendations and guidelines, as well as
the basis for decisions regarding pharmaceutical reimbursement. This
one-of-a-kind report discusses evidence-based medicine in a variety of its
guises, illustrating the pervasive nature of evidence-based decisions in
healthcare and pharmaceutical environments.
In recent years, evidence-based medicine has emerged as one of the most
pertinent topics of discussion within the field of medicine, involving - on
the one hand - patients and - on the other - a variety of healthcare
policy-makers, practitioners and regulators. In the United Kingdom,
evidence-based practice has been implemented in a variety of fields, including
adult medicine, child health, surgery, pathology, pharmacotherapy, nursing,
general practice, and dentistry, as well as in the field of pharmaceutical
reimbursement. Evidence-based medicine has also been practiced by the
governments of Canada and Australia for some time, while Germany, Japan and
the United States have more recently begun to utilize evidence-based medicine
for both private and public reimbursement.
The opening chapters of this report provide a brief history of evidence-based
medicine, main definitions and the limitations and advantages of the concept.
Subsequent chapters discuss the use and applicability of evidence-based
medicine in various therapeutic areas, followed by a discussion of
evidence-based medicine in six major global medical and pharmaceutical
markets. The first three of these (namely Australia, Canada and the United
Kingdom) are seen as pioneers in the utilization of evidence-based medicine,
while the other three (namely Germany, Japan and the United States) have more
recently become interested in wider applicability of such practices.
The final chapter discusses the future prospects for evidence-based medicine,
setting out, on the one hand, the list of factors driving wider application of
such practices. On the other, the report analyses a number of constraints to
the use of evidence-based medicine, which include a range of practical
considerations, such as a lack of time and information overload, as well as
more culture-specific resistance to compliance with imposed guidelines.
What questions does this report answer?
- What is the current status of evidence-based medicine in key global
markets?
- What are the major drivers of wider application of evidence-based medicine?
- What types of evidence-based medicine strategies are currently in use in
various countries around the world?
- What is the anticipated future for evidence-based medicine practices?
- How will the development of expensive new therapeutics stimulate the need
for the implementation of evidence-based medicine?
Highlights of this report
- Discussion of evidence-based medicine in pharmaceutical reimbursement in a
number of key global markets
- Discussion of the future of evidence-based medicine in light of medical
and scientific developments
- Focused analysis of various evidence-based medicine developments in the US
- Identification of key evidence-based medicine resources
- Contributions from industry experts highlighting country-specific cultural
constraints to wider penetration of evidence-based medicine
Key reasons to purchase this report
- The report provides an analytically-focused guide to the global
application of evidence-based medicine
- The report provides a comparison of evidence-based medicine and its
applicability in different countries
- The report provides a scenario for the future use of evidence-based
medicine through the discussion of drivers and constraints
- The report identifies key resources and organizations involved in the
formulation of evidence-based medicine policies
What makes this report topical?
- Increasing need for healthcare and pharmaceutical cost-containment in both
public and private spheres
- Focus on introduction of standards in healthcare
- Rising involvement of patients in their own healthcare and rising demand
for higher quality care
- Increasing use of information technology (IT) in healthcare, which
provides easier access to various data and analysis
- Large investments in new medical technologies and pharmaceuticals
requiring high prices, rendering publicly-funded pharmaceutical reimbursement
highly desirable
Unique features of this report
- Thorough descriptions of key evidence-based medicine practices in major
global medical and pharmaceutical markets
- Discussion of evidence-based medicine' s future from the point of view of
medical advances, not just practical considerations
- Analysis of evidence-based medicine from the point of view of
pharmaceutical reimbursement
- Critical assessment of evidence-based medicine' s advantages and
disadvantages
View Cart
